课题基金 / 基金详情

Novel transcription factor to regulate differentiation of tracheal epithelial cells.

Novel transcription factor to regulate differentiation of tracheal epithelial cells.
调节气管上皮细胞分化的新型转录因子。
批准号:
09672239
负责人:
KAI Hirofumi
金额:
$1.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

KAI Hirofumi的其他基金

相似基金

相关文献

中文摘要
翻译
我们先前克隆并鉴定了牛溶菌酶5A(Lys 5A)启动子,目的是确定控制呼吸道上皮细胞特异性表达的顺式和反式作用元件。我们发现,这种表达是由蛋白质与位于转录起始点-46/-40处的ETS共识序列结合控制的。负责基因反式激活的ETS相关蛋白的身份尚不清楚。在本研究中,我们通过瞬时转染上皮细胞和成纤维细胞筛选了ETS相关蛋白:MEF、ESE-1、Elf-1、Ets-1、Ets-2和PEA 3。结果表明,在这些因子中,MEF对肺上皮细胞(A549)、结肠癌细胞(Caco 2)和皮肤成纤维细胞(NIH3T3)的转录刺激作用最强。使用含有ETS结合位点(-50/-31)的Lys 5A探针对上皮细胞核提取物进行凝胶位移分析,得到一条迁移率缓慢的单一条带。这条带被针对MEF的抗体过度移动,这表明MEF存在于肺上皮细胞A549中,并与Lys 5A启动子中的Ets结合位点结合。支持这一点,我们发现反义MEF mRNA降低了Lys 5A启动子的活性。此外,在稳定的转染体中过表达MEF增加了溶菌酶的mRNA和蛋白的表达。综上所述,这些研究首次提供了确定控制上皮细胞中溶菌酶表达的转录因子的信息。随着细菌对外源性抗生素的耐药性逐渐增强,有关天然免疫控制机制的信息,如上皮溶菌酶提供的机制,可能会提供重要的新治疗方法。
英文摘要
We previously cloned and characterized the bovine lysozyme 5A (lys 5A) promoter with the purpose of determining cis-and trans-acting elements controlling airway epithelial cell-specific expression. We found that such expression is controlled by protein binding to an ets consensus sequence located-at-46/-40 from the transcription start site. The identity of the ets-related protein responsible for gene transactivation was unknown. In the present study, we screened ets-related proteins : MEF, ESE-1, Elf-1, Ets-1, Ets-2, and PEA 3 by transient transfection into epithelial cells and fibroblasts. Results showed that among these factors, MEF most strongly stimulated transcription in lung epithelial cells (A549), colon carcinoma cells (Caco2), and skin fibrobalsts (NIH3T3). Gel shift analysis of epithelial cell nuclear extracts using a lys 5A probe including the ets binding site (-50/-31) yielded a single band with retarded mobility. This band was supershifted by an antibody directed against MEF.This indicated that MEF is present in lung epithelial cells A549 and binds to the ets binding site in the lys 5A promoter. Supporting this, we found that anti-sense MEF mRNA decreased lys 5A promoter activity. Moreover, MEF overexpression in stable transfectants increased lysozyme mRNA and protein expression. In summary, these studies provide the first information identifying a transcription factor controlling lysozyme expression in epithelial cells. As bacteria become progressively more resistant to exogenously applied antibiotics, information regarding mechanisms controlling innate immunity, such as that provided by epithelial lysozyme, may offer important new therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T. Kido, H. Kai, N. Hara, I. Hamamura, Y. Isohama, K. Takahama and T. Miyata: "The use of monoclonal antibodies to quantify airway mucin content in human bronchio-alveolar lavage fluid"Pharm. Pharmacol. Comm.. 4. 219-223 (1998)
T. Kido、H. Kai、N. Hara、I. Hamamura、Y. Isohama、K. Takahama 和 T. Miyata:“使用单克隆抗体定量人支气管肺泡灌洗液中气道粘蛋白含量”Pharm。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Miyata,H.Kai et al.: "Current opinion of muco-active drug research: strategies and problems" Eur.Respir.J.11. 480-491 (1998)
T.Miyata,H.Kai 等:“粘液活性药物研究的当前观点:策略和问题”Eur.Respir.J.11。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
M.Okumuraa, H.Kai, S.Shinozawaa, Y.Isohama, and T.Miyata: "Effects of eosinophil-granule major basic protein on phosphatidylcholine secretion in rat type II pneumocytes" Am.J,Phisiol.(in press).
M.Okumuraa、H.Kai、S.Shinozawaa、Y.Isohama 和 T.Miyata:“嗜酸性粒细胞颗粒主要碱性蛋白对大鼠 II 型肺细胞磷脂酰胆碱分泌的影响”Am.J,Phisiol.(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
H.Kai et al.: "MEF up-regulates lysozyme transcription in epithelial cells" J.Biol.Chem.(印刷中). (1999)
H.Kai 等人:“MEF 上调上皮细胞中的溶菌酶转录”J.Biol.Chem.(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 18 条
    A new preventive way on diseases using electronic chaperones as a novel concept
    • 批准号:
      23650269
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      KAI Hirofumi
    • 依托单位:
    Drug development on protein misfolding diseases
    • 批准号:
      22390015
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.4万
    • 财政年份:
      2010
    • 负责人:
      KAI Hirofumi
    • 依托单位:
    Therapeutic principles on protein misfolding diseases
    • 批准号:
      19390045
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.15万
    • 财政年份:
      2007
    • 负责人:
      KAI Hirofumi
    • 依托单位:
    Development of therapeutic ways targeting molecular chaperones and ets transcription factors
    • 批准号:
      14370748
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.77万
    • 财政年份:
      2002
    • 负责人:
      KAI Hirofumi
    • 依托单位:
    国内基金
    海外基金
    METTL14通过MEF2C m6A修饰改善慢性应激致认知障碍的作用机制研究
    • 批准号:
      2026JJ50273
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      徐杨
    • 依托单位:
    超级增强子NFIX-SE募集MEF2C激活NFIX/NOTCH通路增强肿瘤细胞干性导致小细胞肺癌化疗耐药的机制研究
    • 批准号:
      2026JJ81772
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      童琴
    • 依托单位:
    纺织产品原材料环境足迹(MEF)核算及工具开发
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      邵智娟
    • 依托单位:
    核纤层蛋白PRR14通过转录因子MEF2C维持骨骼肌纤维稳态并参与肌少症的发生发展
    • 批准号:
      2025JJ50154
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      杨眉
    • 依托单位: